Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Giovanni Succo is active.

Publication


Featured researches published by Giovanni Succo.


Cancer | 2001

Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies

Mario Airoldi; Fulvia Pedani; Giovanni Succo; Anna Maria Gabriele; Riccardo Ragona; Sara Marchionatti; Cesare Bumma

Some previous studies have shown that vinorelbine (VNB) is active in recurrent salivary gland tumors.


Laryngoscope | 2006

Subtotal laryngectomy with tracheohyoidopexy : A possible alternative to total laryngectomy

Giuseppe Rizzotto; Giovanni Succo; Marco Lucioni; Toni Pazzaia

Objective: The objective of this study was to describe a new subtotal laryngectomy technique that foresees two variations: 1) tracheohyoidopexy (THIP + A or A‐A)—subtotal removal of the larynx maintaining one or two cricoarytenoid units and subsequent tracheohyoidopexy; and 2) tracheohyoidoepiglottopexy (THIEP + A or A‐A)—resection guarantees preservation of the suprahyoid epiglottis maintaining one or two cricoarytenoid units and further suspension of the tracheal stump at the epiglottis and hyoid bone.


European Archives of Oto-rhino-laryngology | 2001

Pectoralis major myocutaneous flap: analysis of complications in difficult patients

Marco Luigi Castelli; Giancarlo Pecorari; Giovanni Succo; Antonella Bena; Marco Andreis; A. Sartoris

Abstract The purpose of this study was to assess and discuss the effects of old age and systemic diseases on complications related to the use of a pectoralis major myocutaneous flap (PMMF) for reconstruction in head and neck surgery. Eighty-four consecutive patients, operated on between January 1992 and December 1998, were included in the study. Of these patients, 47 were in relatively good condition, while 37were old and frail or affected by systemic diseases. Patients were monitored for complications during a follow-up of 2 years. All patients included in the study had very advanced squamous cell carcinomas (T3-T4) and reconstruction with PMMF was performed after a commando procedure, a total laryngectomy with partial pharyngectomy, or a composite resection. Necrosis of skin island was the most frequently encountered complication, but no surgical intervention was needed. Overall, complications occurred more frequently in patients with underlying pathologies, the risk ratio adjusted for age and sex being 2.94, but 95% confidence intervals were 0.99–8.65 and all complications were minor. In summary, we recommend the use of PMMF for immediate repair in difficult patients who have large oro-pharyngo-laryngeal excisions and radical neck dissections and who suffer concomitantly with various medical problems known to increase complication rates. PMMF proved to be suitable to give these patients good chances of a quick recovery with satisfactory aesthetic and functional results.


European Archives of Oto-rhino-laryngology | 2014

Open partial horizontal laryngectomies: a proposal for classification by the working committee on nomenclature of the European Laryngological Society.

Giovanni Succo; Giorgio Peretti; Cesare Piazza; Marc Remacle; Hans Edmund Eckel; Dominique Chevalier; Ricard Simo; Anastasios Hantzakos; G. Rizzotto; M. Lucioni; Erika Crosetti; Antonino R. Antonelli

We present herein the proposal of the European Laryngological Society working committee on nomenclature for a systematic classification of open partial horizontal laryngectomies (OPHL). This is based on the cranio-caudal extent of laryngeal structures resected, instead of a number of different and heterogeneous variables present in existing nomenclatures, usually referring to eponyms, types of pexy, or inferior limit of resection. According to the proposed classification system, we have defined three types of OPHLs: Type I (formerly defined horizontal supraglottic laryngectomy), Type II (previously called supracricoid laryngectomy), and Type III (also named supratracheal laryngectomy). Use of suffixes “a” and “b” in Type II and III OPHLs reflects sparing or not of the suprahyoid epiglottis. Various extensions to one arytenoid, base of tongue, piriform sinus, and crico-arytenoid unit are indicated by abbreviations (ARY, BOT, PIR, and CAU, respectively). Our proposal is not intended to give a comprehensive algorithm of application of different OPHLs to specific clinical situations, but to serve as the basis for obtaining a common language among the head and neck surgical community. We therefore intend to present this classification system as a simple and intuitive teaching instrument, and a tool to be able to compare surgical series with each other and with non-surgical data.


Radiotherapy and Oncology | 1999

Results of hypofractionated stereotactic re-irradiation on 13 locally recurrent nasopharyngeal carcinomas

Roberto Orecchia; Maria Grazia Ruo Redda; Riccardo Ragona; Daniela Nassisi; Barbara Alicja Jereczek-Fossa; Stefano Zurrida; Mario Bussi; Giovanni Succo; GianLuca Sannazzari

Thirteen patients with locally recurrent, previously-irradiated nasopharyngeal carcinoma were treated with linac-based hypofractionated stereotactic radiotherapy (24 Gy in two or four fractions). One- and 3-year overall survival were 54 and 31%. Three patients were free of disease at 30, 34 and 65 months. No severe acute or late complications were seen.


Tumori | 2002

Carboplatin plus taxol is an effective third-line regimen in recurrent undifferentiated nasopharyngeal carcinoma.

Mario Airoldi; Fulvia Pedani; Sara Marchionatti; Anna Maria Gabriele; Giovanni Succo; Pietro Gabriele; Cesare Bumma

Background Recurrent undifferentiated nasopharyngeal carcinoma is a chemosensitive disease. Few third-line treatments have been reported. Methods Twelve patients (9 males, 3 females; median age 50 years, range, 20-62) with recurrent undifferentiated nasopharyngeal carcinoma were treated with carboplatin AUC 5.5 + paclitaxel (175 mg/m2, 3-hr infusion) on day 1 every 3 weeks. All patients had been previously treated for recurrent disease with a first-line cisplatin-based chemotherapy and a second-line therapy with low-dose continous infusion 5-fluorouracil. Results Overall, 54 courses were given (median, 5; range, 2-6). Three patients (25%) obtained a partial response lasting 6, 10 and 26+ months, 1 (8.3%) a minimal response lasting 6 months, and 3 (25%) no change with a median duration of 5 months. The median survival time was 14 months for patients who had a partial or minimal response or no change, and 5 months for nonresponders. Median overall survival was 9.5 months (3-30+). The treatment was well tolerated, and toxicity was manageable. Conclusions The combination has a good pallitive role as third-line chemotherapy in recurrent undifferentiated nasopharyngeal cancer.


Tumori | 2001

Concomitant chemoradiotherapy followed by adjuvant chemotherapy in parotid gland undifferentiated carcinoma.

Mario Airoldi; Anna Maria Gabriele; Pietro Gabriele; Fulvia Pedani; Sara Marchionatti; Giovanni Succo; Fabio Beatrice; Cesare Bumma

Aims and background Undifferentiated carcinoma of the parotid gland is a poor-prognosis lesion. Results in unresectable lesions, treated with radiotherapy alone, are very disappointing. Methods Six patients with T3-4 N0-1 inoperable lesions were treated with conventional radiotherapy (64-70 Gy, 2 Gy per fraction 5 times a week) and concomitant cisplatin (100 mg/m2, days 1, 22 and 43). Four weeks after radiotherapy, adjuvant chemotherapy (cisplatin, 80 mg/m2, day 1, + VP16, 100 mg/m2, days 1, 3 and 5, q = 3 weeks, for 3 cycles) was given. Results A median dose of 66 Gy (range, 64-70 Gy) was delivered, and all patients recived 3 courses of cisplatin during radiotherapy. Five of 6 patients recived all three chemotherapeutic adjuvant courses. Two months after the end of treatment, 3 CR (50%), 2 PR (33%) and 1 NC (16%) was observed. Median CR and PR duration was 26+ and 10 months, respectively. Median overall survival was 18 months. No severe acute or late toxicity was observed. Conclusions Concomitant chemoradiotherapy followed by adjuvant chemotherapy in advanced unresectable undifferentiated parotid carcinoma is feasibile and well tolerated. The high percentage of long-lasting CR is encouraging.


American Journal of Clinical Oncology | 2003

Docetaxel and vinorelbine in recurrent head and neck cancer: Pharmacokinetic and clinical results

Mario Airoldi; Luigi Cattel; Sara Marchionatti; Valeria Recalenda; Fulvia Pedani; Valentina Tagini; Cesare Bumma; Fabio Beatrice; Giovanni Succo; Anna Maria Gabriele

The purpose of this study was to evaluate pharmacokinetic parameters, efficacy, and toxicity of a combination of docetaxel (DTX) and vinorelbine (VNB) in recurrent heavily pretreated squamous cell head and neck cancer. Twenty-nine patients previously treated with concomitant chemoradiotherapy (n = 14), surgery plus radiotherapy (n = 13), surgery+concomitant chemoradiotherapy (n = 1) and radiotherapy alone (n = 1) were enrolled; 9 patients had received 1 or more courses of palliative chemotherapy. Twenty-one patients had a local–regional recurrence, and 8 patients had metastases. The doses were 80 mg/m2 for DTX and 20 mg/m2 for VNB on day 1 every 21 days for a maximum of 6 cycles. Pharmacokinetic evaluations were performed on 24 patients; in a group of 12 patients, VNB administration immediately followed DTX infusion (schedule A), and in 12 patients VNB administration was immediately followed by DTX infusion (schedule B). Twenty-nine patients received a total of 137 cycles (median per patient, 5). Neutropenia was the most frequent and severe side effect (grade IV in 79%; grade III in 21%). Grade IV (7%) and III (14%) infections were observed in the first 12 patients; ciprofloxacin prophylaxis in the following 17 patients reduced the severe toxicity to 0%. The overall response rate was 49%, which included 3 of 29 complete responses (10%) and 11 of 29 partial responses (38%). Median complete and partial response durations were 20+ and 5.5 months, respectively. Overall median survival was 10 months (range, 2–30+). The mean values of area under the curve, mean residence time (MRT), and Cmax of VNB were significantly lower for schedule A than for schedule B. The mean values of VNB clearance were significantly higher for schedule A than for schedule B. Neutrophil count at the nadir was much lower for patients receiving schedule B. The DTX-VNB combination is effective in heavily pretreated patients with a short-lasting manageable toxicity. Pharmacokinetic evaluations suggested that the sequence DTX → VNB is safer than the sequence VNB → DTX.


Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2016

Benefits and drawbacks of open partial horizontal laryngectomies, part B: Intermediate and selected advanced stage laryngeal carcinoma

Giovanni Succo; Erika Crosetti; Andy Bertolin; Marco Lucioni; Giulia Arrigoni; Valentina Panetta; Andrea Elio Sprio; Giovanni Nicolao Berta; Giuseppe Rizzotto

Cancer of the larynx in the intermediate/advanced stage still presents a major challenge in terms of controlling the disease and preserving the organ. Among therapeutic options, open partial horizontal laryngectomy is proposed as a function‐sparing surgical technique.


Tumori | 1995

Head and neck metastases of renal cancer after nephrectomy: a report of 2 cases.

Mario Airoldi; Giovanni Succo; Guido Valente; Andrea Luigi Cavalot; Pietro Gabriele; Cesare Bumma

Two cases of metachronous metastases of renal cell adenocarcinoma are reported. One case presented a solitary metastasis of the ethmoid-orbit which was resected. The patient has remained well for the following 12 months. The second case presented with a secondary to the tongue and multiple metastases elsewhere. Electrodissection achieved a good palliative result.

Collaboration


Dive into the Giovanni Succo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge